Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | NPC1 | O15118 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | MAOA | P21397 | 1/20 | 0.69 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.69 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.61 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.61 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9627098 | 0.90 | MTNR1A (0.67) | RAB9AKDM4ENPC1LMNATP53 | |
| SCHEMBL7332474 | 0.88 | TAAR1 (0.61) | RAB9AMTNR1AMTNR1BTAAR1HDAC1 | |
| SCHEMBL346302 | 0.86 | FFAR1 (0.65) | RAB9ALMNACYP1A2MTNR1AMTNR1B | |
| SCHEMBL9626622 | 0.85 | MAOB (0.65) | RAB9AKDM4ENPC1LMNATP53 | |
| SCHEMBL13314605 | 0.85 | ALDH1A1 (0.55) | RAB9AKDM4ENPC1LMNATP53 | |
| SCHEMBL3257076 | 0.85 | HDAC1 (0.57) | RAB9ASMN1; SMN2MTNR1AMTNR1BTAAR1 | |
| SCHEMBL7979541 | 0.85 | HDAC1 (0.57) | RAB9AMTNR1AMTNR1BTAAR1HDAC1 | |
| SCHEMBL660540 | 0.85 | TAAR1 (0.62) | RAB9AMTNR1AMTNR1BTAAR1HDAC1 | |
| SCHEMBL63100 | 0.85 | HDAC1 (0.61) | RAB9ACYP1A2MTNR1AMTNR1BTAAR1 | |
| SCHEMBL13545161 | 0.85 | MTNR1A (0.61) | RAB9AMTNR1AMTNR1BTAAR1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11964935-B2 | Gingerol derivative having inhibitory activity against biofilm formation and pharmaceutical composition comprising same as effective ingredient for preventing or treating biofilm-caused infection symptom | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION, SEJONG CAMPUS (KR) | 2024-04-23 | — | — | US | disclosed |
| US-11746364-B2 | Enzymatic synthesis of kavalactones and flavokavains | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2023-09-05 | — | — | US | disclosed |
| US-11739354-B2 | Enzymatic synthesis of kavalactones and flavokavains | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2023-08-29 | — | — | US | disclosed |
| CN-113912556-B | Synthesis method of alpha, beta-dicarbonyl-1, 2, 3-triazole compound | 武汉工程大学 | 2023-06-09 | — | — | CN | disclosed |
| CN-113912556-A | Synthetic method of alpha, beta-dicarbonyl-1, 2, 3-triazole compound | 武汉工程大学 | 2022-01-11 | — | — | CN | disclosed |
| US-10787484-B2 | Compositions and methods for treating cardiovascular disease | GENENTECH, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20200283364-A1 | GINGEROL DERIVATIVE HAVING INHIBITORY ACTIVITY AGAINST BIOFILM FORMATION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE INGREDIENT FOR PREVENTING OR TREATING BIOFILM-CAUSED INFECTION SYMPTOM | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION, SEJONG CAMPUS (KR) | 2020-09-10 | — | — | US | disclosed |
| US-20190177366-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | GENENTECH, INC. (US) | 2019-06-13 | — | — | US | disclosed |
| US-20170210734-A1 | Substituted Azaspiro(4.5)Decane Derivatives | GRUENENTHAL GMBH (DE) | 2017-07-27 | — | — | US | disclosed |
| EP-1933622-B1 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | SECOND GENOME INC (US) | 2016-03-09 | — | — | EP | disclosed |
| US-4960798-A | Methods for the treatment of angina | MCNEILAB, INC. (US) | 1990-10-02 | — | — | US | disclosed |
| US-4898889-A | Methods for the treatment of hypertension | MCNEILAB, INC. (US) | 1990-02-06 | — | — | US | disclosed |
| US-4742084-A | Aralykyl (arylethynyl)aralkyl amines and their use as vasodilators and antihypertensives | MCNEILAB, INC. (US) | 1988-05-03 | — | — | US | disclosed |
| EP-0155079-B1 | ACETYLENE AMINES AND THEIR USE AS VASODILATORS AND ANTIHYPERTENSIVES | McNeilab, Inc. (US) | 1988-02-17 | — | — | EP | disclosed |
| US-4725602-A | Acetylene amines and their use as vasodilators and antihypertensives | MCNEILAB, INC. (US) | 1988-02-16 | — | — | US | disclosed |
| EP-0250254-A1 | Cis & trans stilbenes and their composition for the treatment of hypertension | McNeilab, Inc. (US) | 1987-12-23 | — | — | EP | disclosed |
| US-4661635-A | ANTIARRHYTHMIA AGENTS | MCNEILAB, INC. (US) | 1987-04-28 | — | — | US | disclosed |
| EP-0155079-A1 | Acetylene amines and their use as vasodilators and antihypertensives | McNeilab, Inc. (US) | 1985-09-18 | — | — | EP | disclosed |
| EP-0146271-A2 | Aralykyl (arylethynyl) aralkyl amines for use as vasodilators and antihypertensives | McNeilab, Inc. (US) | 1985-06-26 | — | — | EP | disclosed |
| EP-0145361-A2 | Acetylene derivatives for the treatment of hypertension and angina | McNeilab, Inc. (US) | 1985-06-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210734-A1 | Substituted Azaspiro(4.5)Decane Derivatives | OPRL1, OPRM1, OPRD1 | RAB9A 4272/4885KDM4E 2287/4885NPC1 2092/4885 |
| US-10787484-B2 | Compositions and methods for treating cardiovascular disease | PCSK9, PCSK7, PCSK6 | RAB9A 2667/4885KDM4E 2270/4885NPC1 161/4885 |
| US-20200283364-A1 | GINGEROL DERIVATIVE HAVING INHIBITORY ACTIVITY AGAINST BIOFILM FORMATION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE INGREDIENT FOR PREVENTING OR TREATING BIOFILM-CAUSED INFECTION SYMPTOM | LSS, F2R, CFTR | RAB9A 1134/4885KDM4E 4545/4885NPC1 794/4885 |
| US-20190177366-A1 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE | PCSK9, PCSK7, PCSK6 | RAB9A 2667/4885KDM4E 2270/4885NPC1 161/4885 |
| US-11964935-B2 | Gingerol derivative having inhibitory activity against biofilm formation and pharmaceutical composition comprising same as effective ingredient for preventing or treating biofilm-caused infection symptom | LSS, F2R, CFTR | RAB9A 1134/4885KDM4E 4545/4885NPC1 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.